Status:
ACTIVE_NOT_RECRUITING
Patient-derived Glioma Stem Cell Organoids
Lead Sponsor:
Maastricht Radiation Oncology
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Brief Summary
Rationale: Glioblastoma (GM) is the most frequent incurable adult brain tumor with median survival of 15 months after diagnosis, despite extensive treatment with surgery, radiation therapy and chemoth...
Detailed Description
Patients with glioblastoma (GM) have a median overall survival of approximately 15 months.Standard therapy for GM encompasses maximum surgical resection followed by radiation and chemotherapy using te...
Eligibility Criteria
Inclusion
- MRI imaging suggestive for glioblastoma
- \> 18 years of age
Exclusion
- Karnofsky index \< 70
- Clotting disorders
- Neurosurgical contraindications for gross total resection
Key Trial Info
Start Date :
April 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04868396
Start Date
April 10 2021
End Date
September 1 2025
Last Update
November 20 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht UMC+
Maastricht, Limburg, Netherlands, 6202AZ
2
Maastricht Radiation Oncology
Maastricht, Limburg, Netherlands, 6229ET